Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/25
Recursion Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/25
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp BurdenGlobeNewsWire • 05/04/25
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5thGlobeNewsWire • 04/28/25
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025GlobeNewsWire • 04/23/25
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?The Motley Fool • 04/18/25
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World DataPRNewsWire • 04/16/25
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?Zacks Investment Research • 04/14/25
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in MarchThe Motley Fool • 04/03/25
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged TodayThe Motley Fool • 03/31/25
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?The Motley Fool • 03/30/25
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI StocksThe Motley Fool • 03/30/25
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?Zacks Investment Research • 03/18/25